2-[3,5-双(三氟甲基)苯基]乙胺 | 181772-08-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-[3,5-双(三氟甲基)苯基]乙胺
• 英文名称: 2-(3,5-bis(trifluoromethyl)phenyl)ethan-1-amine
• 英文别名: 2-(3,5-Bis-trifluoromethyl-phenyl)-ethylamine；(3,5-bis-trifluoromethyl-benzyl)methyl-amin；3,5-Bis(trifluoromethyl)-benzeneethanamine；2-[3,5-bis(trifluoromethyl)phenyl]ethanamine
• CAS: 181772-08-7
• 化学式: C₁₀H₉F₆N
• mdl: MFCD06212603
• 分子量: 257.179
• InChiKey: QJNMFINEIFVNMK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2-[3,5-双(三氟甲基)苯基]乙胺 在 聚碳化二亚胺 、 sodium hydride 、 1-羟基苯并三唑 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 生成 N-[2-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-N-methyl-3,3-diphenyl-propionamide
  参考文献：
  名称：

  Linear amides as substance P antagonists

  摘要：

  In the present study we demonstrate that an amide linking group provides an excellent template for the positioning of a benzhydryl group and a suitably functionalized aromatic ring in an orientation which allows for high affinity binding to the hNK(1) receptor. Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/s0960-894x(96)00280-6
• 作为产物：
  描述：

  1-(2-nitroethyl)-3,5-bis(trifluoromethyl)benzene 在 palladium 10% on activated carbon 、 氢气 作用下， 以 乙醇 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 5.0h， 以100%的产率得到2-[3,5-双(三氟甲基)苯基]乙胺
  参考文献：
  名称：

  Design, Synthesis, and Efficacy Testing of Nitroethylene- and 7-Nitrobenzoxadiazol-Based Flavodoxin Inhibitors against Helicobacter pylori Drug-Resistant Clinical Strains and in Helicobacter pylori-Infected Mice

  摘要：

  Helicobacter pylori (Hp) infection is the main cause of peptic ulcer and gastric cancer. Hp eradication rates have fallen due to increasing bacterial resistance to currently used broad-spectrum antimicrobials. We have designed, synthesized, and tested redox variants of nitroethylene- and 7-nitrobenzoxadiazole-based inhibitors of the essential Hp protein flavodoxin. Derivatives of the 7-nitrobenzoxadiazole lead, carrying reduced forms of the nitro group and/or oxidized forms of a sulfur atom, display high therapeutic indexes against several reference Hp strains. These inhibitors are effective against metronidazole-, clarithromycin-, and rifampicin-resistant Hp clinical isolates. Their toxicity for mice after oral administration is low, and, when administered individually at single daily doses for 8 days in a mice model of Hp infection, they decrease significantly Hp gastric colonization rates and are able to eradicate the infection in up to 60% of the mice. These flavodoxin inhibitors constitute a novel family of Hp-specific antimicrobials that may help fight the constant increase of Hp antimicrobial-resistant strains.

  DOI：

  10.1021/acs.jmedchem.9b00355

文献信息

• [EN] 1,2,4-SUBSTITUERTE 1,2,3,4-TETRAHYDRO-AND 1,2 DIHYDRO-QUINOLINE AND 1,2,3,4-TETRAHYDRO-QUINOXALINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND OBESITY<br/>[FR] DERIVES DE 1,2,3,4-TETRAHYDRO- ET 1,2 DIHYDRO-QUINOLEINE ET 1,2,3,4-TETRAHYDRO-QUINOXALINE 1,2,4-SUBSTITUES, UTILES COMME INHIBITEURS DE CETP POUR LE TRAITEMENT DE L'ATHEROSCLEROSE ET DE L'OBESITE
  申请人：PFIZER PROD INC

  公开号：WO2004085401A1

  公开（公告）日：2004-10-07

  Quinoline and quinoxaline compounds of formula I and III wherein the subtituent are as defined in claims 1 and 15, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

  喹啉和喹啉并喹啉化合物的公式I和III，其中取代基如权利要求1和15中所定义的，含有这种化合物的药物组合物以及使用这种化合物来提高某些血浆脂质水平，包括高密度脂蛋白胆固醇，并降低其他一些血浆脂质水平，如LDL胆固醇和甘油三酯，并因此治疗由HDL胆固醇水平低和/或LDL胆固醇和甘油三酯水平高加重的疾病，如动脉粥样硬化和心血管疾病在某些哺乳动物中，包括人类。
• [EN] INDOLINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF ARTERIOSCLEROSIS<br/>[FR] COMPOSES A BASE D'INDOLINE ET LEUR UTILISATION DANS LE TRAITEMENT DE L'ARTERIOSCLEROSE
  申请人：PFIZER PROD INC

  公开号：WO2006032987A1

  公开（公告）日：2006-03-30

  Indoline compounds, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

  吲哚啉化合物，含有这种化合物的药物组合物，以及使用这种化合物来提高某些血浆脂质水平，包括高密度脂蛋白胆固醇，并降低其他一些血浆脂质水平，如低密度脂蛋白胆固醇和甘油三酯，并据此治疗由高密度脂蛋白胆固醇水平低和/或低密度脂蛋白胆固醇和甘油三酯水平高加重的疾病，如动脉粥样硬化和心血管疾病在某些哺乳动物中，包括人类。
• [EN] UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS<br/>[FR] COMPOSÉS D'URÉE ACYCLIQUES SERVANT DE MODULATEURS DE LA GAMMA-SÉCRÉTASE
  申请人：AMGEN INC

  公开号：WO2009137404A1

  公开（公告）日：2009-11-12

  The present invention provides compounds Formula (I) that are gamma secretase modulators and are therefore useful for the treatment of diseases treatable by modulation of gamma secretase such as Alzheimer's disease. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  本发明提供了化合物Formula (I)，它们是γ-分泌酶调节剂，因此可用于治疗通过调节γ-分泌酶可治疗的疾病，如阿尔茨海默病。还提供了含有这些化合物的药物组合物以及制备这些化合物的方法。
• Structure-Based Design, Synthesis, and A-Site rRNA Cocrystal Complexes of Functionally Novel Aminoglycoside Antibiotics:  C2‘ ‘ Ether Analogues of Paromomycin
  作者：Stephen Hanessian、Janek Szychowski、Susanta Sekhar Adhikari、Guillermo Vasquez、Pachamuthu Kandasamy、Eric E. Swayze、Michael T. Migawa、Ray Ranken、Boris François、Julia Wirmer-Bartoschek、Jiro Kondo、Eric Westhof

  DOI：10.1021/jm061200+

  日期：2007.5.1

  A series of 2"-O-substituted ether analogues of paromomycin were prepared based on new site-selective functionalizations. X-ray cocrystal complexes of several such analogues revealed a new mode of binding in the A-site rRNA, whereby rings I and II adopted the familiar orientation and position previously observed with paromomycin, but rings III and IV were oriented differently. With few exceptions,

  根据新的位点选择性功能化，制备了一系列2'-O-取代的巴龙霉素醚类似物。几种类似物的X射线共晶复合物揭示了在A位rRNA中的新结合方式，即环I和II采用了以前对巴龙霉素观察到的熟悉的方向和位置，但环III和IV的取向不同，除少数例外，所有这些新类似物对敏感的金黄色葡萄球菌均表现出与巴龙霉素相同或更好的抑制活性。获得了针对大肠杆菌的MIC值，其中一些醚附件含有极性或碱性端基；两种类似物在小鼠败血病保护试验中显示出优异的存活率；对肾脏的初步组织病理学分析未显示明显的毒性迹象，而使用新霉素和卡那霉素的对照组在较低剂量下有毒。
• [EN] PERIPHERAL ALKYL AND ALKENYL CHAINS EXTENDED BENZENE DERIVATIVES AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME<br/>[FR] DÉRIVÉS BENZÉNIQUES À CHAÎNES ALKYLE ET ALCÉNYLE PÉRIPHÉRIQUES ÉTENDUES ET COMPOSITION PHARMACEUTIQUE COMPRENANT CEUX-CI
  申请人：TAIWANJ PHARMACEUTICALS CO LTD

  公开号：WO2020205455A1

  公开（公告）日：2020-10-08

  The compounds represented by Formula (I), which are peripheral alkyl and alkenyl chains extended benzene derivatives, are useful as dual autotaxin (ATX) / histone deacetylase (HD AC) inhibitors. These compounds may be included in a pharmaceutical composition along with a pharmaceutically acceptable carrier, and be used in a therapeutically effective amount for prophylaxis or treatment of various diseases and disorders.

  由公式（I）代表的化合物是外周烷基和烯基链延伸的苯衍生物，可作为双重自动税林(ATX) / 组蛋白去乙酰化酶(HDAC)抑制剂而有用。这些化合物可以与药学上可接受的载体一起组成药物组合物，并以治疗有效量用于预防或治疗各种疾病和疾病。